Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review

<div>Clinical course of this patient. mPSL, methylprednisolone; PSL, prednisolone; IV-CsA, continuous intravenous infusion of cyclosporine A; oral-CsA, oral administration of cyclosporine A; IVCY, intravenous infusion of cyclophosphamide; RTX, rituximab.</div>

Case Reports in Rheumatology

fig4

Figure 4

Figure 4: Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 

Figure 4 | Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 